OTCMKTS:BLUSF BELLUS Health (BLUSF) Stock Price, News & Analysis → Urgent dollar warning (From Stansberry Research) (Ad) Free BLUSF Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$6.46▼$14.5152-Week Range N/AVolume3.45 million shsAverage Volume39,610 shsMarket Capitalization$2.35 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get BELLUS Health alerts: Email Address Ad AltimetryUrgent Nvidia WarningCould Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.Click here to access… About BELLUS Health Stock (OTCMKTS:BLUSF)BELLUS Health, Inc. is a biopharmaceutical development company, which engages in the research and development of products that provide health solutions and address critical unmet medical needs. Its products include BLU-5937, KIACTA, AMO-01, and ALZ-801. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.Read More Ad AltimetryUrgent Nvidia WarningCould Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.Click here to access… BLUSF Stock News HeadlinesApril 29, 2024 | msn.comWatercolor Blush Is The Most Natural Technique For Rosy CheeksApril 27, 2024 | yahoo.comMichelle Pfeiffer Reveals Her "All Time" Favorite Creamy BlushMay 3, 2024 | Stansberry Research (Ad)Urgent dollar warningYour 2024 Election Money Blueprint Voters are angrier than ever, and it's likely to keep getting worse. The media and Wall Street keep declaring how great the economy supposedly is... but no one – besides the ultra-rich – seems to feel that way. Protect yourself with this one simple move today.April 15, 2024 | msn.comThis Viral Powder Blush Will Make You Give Up Your CreamsApril 13, 2024 | yahoo.comIf You Only Use 1 Blush for the Rest of Your Life, It Should Be This Powder-Cream DuoNovember 8, 2023 | morningstar.comNatura &Co Holding SA ADR NTCOOctober 24, 2023 | health.usnews.comRaymond R. BlushJune 16, 2023 | benzinga.comBELLUS Health Inc. Announces Voting Results from Special Meeting of ShareholdersMay 3, 2024 | Stansberry Research (Ad)Urgent dollar warningYour 2024 Election Money Blueprint Voters are angrier than ever, and it's likely to keep getting worse. The media and Wall Street keep declaring how great the economy supposedly is... but no one – besides the ultra-rich – seems to feel that way. Protect yourself with this one simple move today.May 12, 2023 | msn.comBELLUS Health: Q1 Earnings InsightsApril 19, 2023 | markets.businessinsider.comWhere BELLUS Health Stands With AnalystsApril 18, 2023 | msn.comGSK to Buy Bellus for $2 Billion to Gain Cough MedicineApril 5, 2023 | seekingalpha.comBellus Health posts proof-of-concept data for cough candidateApril 5, 2023 | markets.businessinsider.comBELLUS: Phase 1 Study Establishes Proof Of Concept For Developing ER Formulation Of CamlipixantApril 5, 2023 | markets.businessinsider.comBELLUS: Phase 1 Study Establishes Proof Of Concept For Developing ER Formulation Of CamlipixantNovember 14, 2022 | benzinga.comBELLUS Health Reports Third Quarter 2022 Financial Results and Business HighlightsNovember 14, 2022 | msn.comBellus Health (BLU) Reports Q3 Loss, Misses Revenue EstimatesOctober 10, 2022 | yahoo.comBELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the CHEST Annual MeetingJuly 18, 2022 | benzinga.comBELLUS Health Closes US$153 Million Public Offering of Common Shares in Canada and the United StatesMarch 10, 2022 | gurufocus.comPower Corp of Canada Buys BELLUS Health Inc, Sells Alibaba Group Holding, New Oriental ...February 17, 2022 | gurufocus.comFirst Light Asset Management, LLC Buys AtriCure Inc, Keros Therapeutics Inc, BELLUS Health Inc, ...September 13, 2021 | benzinga.comWhat's Going On With BELLUS Health's Stock Today?See More Headlines Receive BLUSF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BELLUS Health and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2019Today5/03/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry N/A Sub-IndustryN/A Current SymbolOTCMKTS:BLUSF CUSIPN/A CIKN/A Webwww.bellushealth.com Phone45-0680-4500FaxN/AEmployees10Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,010,000.00 Net Margins-49,910.34% Pretax MarginN/A Return on Equity-48.37% Return on Assets-45.25% Debt Debt-to-Equity RatioN/A Current Ratio13.87 Quick Ratio13.87 Sales & Book Value Annual Sales$30,000.00 Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.25 per share Price / BookN/AMiscellaneous Outstanding Shares159,117,000Free FloatN/AMarket Cap$2.35 billion OptionableNot Optionable Beta1.55 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesRoberto BelliniPresident, Chief Executive Officer & DirectorFrançois DesjardinsVice President-FinanceDenis GarceauSenior Vice President-Drug DevelopmentTony MatzouranisVice President-Business DevelopmentSébastien RoySecretaryKey CompetitorsTandem Diabetes CareNASDAQ:TNDMLifeStance Health GroupNASDAQ:LFSTVera TherapeuticsNASDAQ:VERADenali TherapeuticsNASDAQ:DNLIICU MedicalNASDAQ:ICUIView All Competitors BLUSF Stock Analysis - Frequently Asked Questions How were BELLUS Health's earnings last quarter? BELLUS Health Inc (OTCMKTS:BLUSF) released its quarterly earnings data on Wednesday, May, 8th. The company reported ($0.02) earnings per share for the quarter, missing the consensus estimate of ($0.01) by $0.01. The business had revenue of $0.01 million for the quarter. BELLUS Health had a negative net margin of 49,910.34% and a negative trailing twelve-month return on equity of 48.37%. This page (OTCMKTS:BLUSF) was last updated on 5/3/2024 by MarketBeat.com Staff From Our PartnersThe AI stock to buy right nowStockEarningsUrgent Nvidia WarningAltimetryThe A.I. story nobody is telling you (Read ASAP)TradeSmithCould Your Accounts Be Frozen?Allegiance GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsREAD THIS – If You Missed Out On The AI BoomBanyan Hill Publishing$5,000 Gold?Stansberry ResearchBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BELLUS Health Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
